Advertisement

AIDS and Behavior

, Volume 23, Supplement 1, pp 32–40 | Cite as

Making the Connection: Using Videoconferencing to Increase Linkage to Care for Incarcerated Persons Living with HIV Post-release

  • Antoine D. BrantleyEmail author
  • Karissa M. Page
  • Barry Zack
  • Kira Radtke Friedrich
  • Deborah Wendell
  • William T. Robinson
  • DeAnn Gruber
Original Paper

Abstract

Incarcerated persons living with HIV (PLWH) have relatively high levels of HIV care engagement and antiretroviral therapy adherence during incarceration, but few are able to maintain these levels upon reentry into the community. In Louisiana, PLWH nearing release from prisons were offered video conferences with case managers housed in community based organizations aimed at facilitating linkage to care in the community. Of the 144 persons who received a video conference during the study period, 74.3% had linked to HIV care in the community within 90 days after release. Compared to the comparison group (n = 94), no statistically significant difference in linkage rate was detected (p > 0.05). Nonetheless, the video conference supplement was positively received by clients and case management agencies in the community and the lack of a detectable impact may be due to early difficulties in intervention delivery and study design limitations. Further study is needed to determine the value of the video conferencing supplement in other settings.

Keywords

Incarceration Telemedicine Linkage to care HIV Case management 

Notes

Acknowledgements

This publication was supported by Grant No. H97HA22694 funded by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) in the amount of $1,855,873 awarded to the Louisiana Department of Health – Office of Public Health – STD/HIV Program. No percentage of this project was financed with non-governmental sources. The contents are solely the responsibility of the authors and do not necessarily represent the official views of HRSA, HHS, or the U.S. Government. The authors wish to thank Raman Singh, MD, Medical/Mental Health Director for the Louisiana Department of Public Safety and Corrections, for his resolute support of the intervention. The authors would also like to thank the staff of the Louisiana Department of Health, Office of Public Health – STD/HIV Program; Louisiana’s Ryan White Part A and Part B case management agencies, the Louisiana Department of Public Safety and Corrections, the Louisiana State University Health Care Services Division’s Telemedicine program, and the clients who participated in the intervention for their many contributions to the intervention.

Funding

This project was funded by the U.S. Department of Health and Human Services, Human Services and Resources Administration, HIV/AIDS Bureau, Ryan White Part F Special Projects of National Significance (Grant #H97HA22694).

Compliance with Ethical Standards

Conflict of interest

Karissa M. Page has received an honorarium for participation in a regional focus group pertaining to this intervention from Gilead Sciences, Inc. The remaining authors declare that they have no conflict of interest.

Informed Consent

Informed consent adhering to the tenants of the Declaration of Helsinki was obtained from all individuals participants included in this intervention.

References

  1. 1.
    Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020. 2017. https://files.hiv.gov/s3fs-public/nhas-update.pdf. Accessed 10 Feb 2017.
  2. 2.
    Greenberg AE, Purcell DW, Gordon CM, Barasky RJ, del Rio C. Addressing the challenges of the HIV continuum of care in high-prevalence cities in the United States. J Acquir Immune Defic Syndr. 2015;1(69 Suppl 1):S1–7.CrossRefGoogle Scholar
  3. 3.
    Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMedGoogle Scholar
  4. 4.
    The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRefGoogle Scholar
  6. 6.
    Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24(10):1263–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mangal JP, Rimland D, Marconi VC. The continuum of HIV care in a Veterans’ Affairs clinic. AIDS Res Hum Retroviruses. 2014;30(5):409–15.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Doshi RK, Milberg J, Isenberg D, Matthews T, Malitz F, Matosky M, et al. High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV/AIDS Program, 2011. Clin Infect Dis. 2015;60(1):117–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Office of Disease Prevention and Health Promotion. Healthy people 2020—HIV. 2017. https://www.healthypeople.gov/2020/topics-objectives/topic/hiv. Accessed 10 Feb 2017.
  11. 11.
    U.S. Department of Health and Human Services. About the Ryan White HIV/AIDS Program. 2016. https://hab.hrsa.gov/about-ryan-white-hivaids-program/about-ryan-white-hivaids-program#. Accessed 10 Mar 2017.
  12. 12.
    Dailey AF, Johnson AS, Wu B. HIV care outcomes among blacks with diagnosed HIV—United States, 2014. MMWR Morb Mortal Wkly Rep. 2017;66(97):97.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. South Med J. 2007;100(8):775–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Dombrowski JC, Simoni JM, Katz DA, Golden MR. Barriers to HIV care and treatment among participants in a public health HIV care relinkage program. AIDS Patient Care STDS. 2015;29(5):279–87.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Maulsby C, Millett G, Lindsey K, Kelley R, Johnson K, Montoya D, et al. HIV among Black men who have sex with men (MSM) in the United States: a review of the literature. AIDS Behav. 2014;18(1):10–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, et al. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2012;16(3):711–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fullilove MT, Fullilove RE. Stigma as an obstacle to AIDS action. Am Behav Sci. 1999;42(7):1117–29.CrossRefGoogle Scholar
  19. 19.
    Kates J, Ranji U, Beamesderfer A, Salganicoff A, Dawson L. Health and access to care and coverage for lesbian, gay, bisexual, and transgender individuals in the U.S. 2017. http://files.kff.org/attachment/Issue-Brief-Health-and-Access-to-Care-and-Coverage-for-LGBT-Individuals-in-the-US. Accessed 10 Feb 2017.
  20. 20.
    Graham JL, Giordano TP, Grimes RM, Slomka J, Ross M, Hwang LY. Influence of trust on HIV diagnosis and care practices: a literature review. J Int Assoc Physicians AIDS Care (Chic). 2010;9(6):346–52.CrossRefGoogle Scholar
  21. 21.
    Reidpath DD, Chan KY. A method for the quantitative analysis of the layering of HIV-related stigma. AIDS Care. 2005;17(4):425–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Milloy MJ, Montaner JS, Wood E. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep. 2014;11(3):308–16.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration in the United States. N Engl J Med. 2011;364(22):2081–3.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Maruschak L, Bronson J. HIV in prisons, 2015—statistical tables. 2017; NCJ 250641.Google Scholar
  26. 26.
    Centers for Disease Control and Prevention. HIV surveillance report, 2015. 2016; 27.Google Scholar
  27. 27.
    Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26(1):10–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105(7):e5–16.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lucas KD, Eckert V, Behrends CN, Wheeler C, MacGowan RJ, Mohle-Boetani JC. Evaluation of routine HIV opt-out screening and continuum of care services following entry into eight prison reception centers-California, 2012. MMWR Morb Mortal Wkly Rep. 2016;65(7):178–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):721–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8(4):205–12.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301(8):848–57.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Brinkley-Rubinstein L, Turner WL. Health impact of incarceration on HIV-positive African American males: a qualitative exploration. AIDS Patient Care STDS. 2013;27(8):450–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Stephenson BL, Wohl DA, McKaig R, Golin CE, Shain L, Adamian M, et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS. 2006;17(2):103–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Binswanger IA, Mueller SR, Beaty BL, Min SJ, Corsi KF. Gender and risk behaviors for HIV and sexually transmitted infections among recently released inmates: a prospective cohort study. AIDS Care. 2014;26(7):872–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract 2012;7:3-0640-7-3.Google Scholar
  38. 38.
    Kinner SA, Milloy MJ, Wood E, Qi J, Zhang R, Kerr T. Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. Addict Behav. 2012;37(6):691–6.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Dennis AC, Barrington C, Hino S, Gould M, Wohl D, Golin CE. “You’re in a world of chaos”: experiences accessing HIV care and adhering to medications after incarceration. J Assoc Nurses AIDS Care. 2015;26(5):542–55.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Rozanova J, Brown SE, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice. 2015;18(3):18.CrossRefGoogle Scholar
  41. 41.
    Uggen C, Manza J, Behrens A. “Less than the average citizen”: stigma, role transition, and the civic reintegration of convicted felons. In: Maruna S, editor. After crime and punishment: ex-offender reintegration and desistance from crime. London: Willan Publishing; 2004.Google Scholar
  42. 42.
    Kemnitz R, Kuehl TC, Hochstatter KR, Barker E, Corey A, Jacobs EA, et al. Manifestations of HIV stigma and their impact on retention in care for people transitioning from prisons to communities. Health Justice 2017;5(1):7-017-0054-1.Google Scholar
  43. 43.
    Haley DF, Golin CE, Farel CE, Wohl DA, Scheyett AM, Garrett JJ, et al. Multilevel challenges to engagement in HIV care after prison release: a theory-informed qualitative study comparing prisoners’ perspectives before and after community reentry. BMC Public Health 2014;14:1253-2458-14-1253.Google Scholar
  44. 44.
    Brinkley-Rubinstein L. Understanding the effects of multiple stigmas among formerly incarcerated HIV-positive African American men. AIDS Educ Prev. 2015;27(2):167–79.CrossRefPubMedGoogle Scholar
  45. 45.
    Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community—a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials. 2012;33(2):436–44.CrossRefPubMedGoogle Scholar
  46. 46.
    Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Hammett TM, Donahue S, LeRoy L, Montague BT, Rosen DL, Solomon L, et al. Transitions to care in the community for prison releasees with HIV: a qualitative study of facilitators and challenges in two states. J Urban Health. 2015;92(4):650–66.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011;53(5):469–79.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Zelenev A, Marcus R, Kopelev A, Cruzado-Quinones J, Spaulding A, Desabrais M, et al. Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav. 2013;17(Suppl 2):S181–94.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Spaulding AC, Messina LC, Kim BI, Chung KW, Lincoln T, Teixeira P, et al. Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release. AIDS Behav. 2013;17(Suppl 2):S203–11.CrossRefPubMedGoogle Scholar
  51. 51.
    Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17(Suppl 2):S156–70.CrossRefPubMedGoogle Scholar
  52. 52.
    Booker CA, Flygare CT, Solomon L, Ball SW, Pustell MR, Bazerman LB, et al. Linkage to HIV care for jail detainees: findings from detention to the first 30 days after release. AIDS Behav. 2013;17(Suppl 2):S128–36.CrossRefPubMedGoogle Scholar
  53. 53.
    Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–8.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wohl DA, Scheyett A, Golin CE, White B, Matuszewski J, Bowling M, et al. Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial. AIDS Behav. 2011;15(2):356–64.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lincoln T, Kennedy S, Tuthill R, Roberts C, Conklin TJ, Hammett TM. Facilitators and barriers to continuing healthcare after jail: a community-integrated program. J Ambul Care Manag. 2006;29(1):2–16.CrossRefGoogle Scholar
  56. 56.
    Sidibe T, Golin C, Turner K, Fray N, Fogel C, Flynn P, et al. Provider perspectives regarding the health care needs of a key population: HIV-infected prisoners after incarceration. J Assoc Nurses AIDS Care. 2015;26(5):556–69.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    SAS Institute Inc. SAS for Windows. 2002–2010; Release 9.3.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Antoine D. Brantley
    • 1
    Email author
  • Karissa M. Page
    • 1
    • 2
  • Barry Zack
    • 3
  • Kira Radtke Friedrich
    • 1
    • 4
  • Deborah Wendell
    • 1
    • 4
  • William T. Robinson
    • 1
    • 4
  • DeAnn Gruber
    • 1
  1. 1.Louisiana Department of Health – Office of Public Health STD/HIV ProgramNew OrleansUSA
  2. 2.Louisiana Department of Health – Bureau of Health Services FinancingBaton RougeUSA
  3. 3.The Bridging Group, LLCOaklandUSA
  4. 4.Louisiana State University Health Sciences Center at New OrleansNew OrleansUSA

Personalised recommendations